Provided by Tiger Trade Technology Pte. Ltd.

Esperion Therapeutics

3.33
-0.1500-4.31%
Volume:2.33M
Turnover:7.88M
Market Cap:796.08M
PE:-6.22
High:3.53
Open:3.48
Low:3.29
Close:3.48
52wk High:4.18
52wk Low:0.6925
Shares:239.06M
Float Shares:237.00M
Volume Ratio:0.79
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5358
EPS(LYR):-0.2764
ROE:97.76%
ROA:-5.42%
PB:-1.76
PE(LYR):-12.05

Loading ...

Esperion Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Dec 10, 2025

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

GlobeNewswire
·
Dec 10, 2025

Esperion Therapeutics Shares Rise After Piper Sandler Initiates Coverage

MT Newswires Live
·
Nov 26, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Applied Materials, CDW,  Kohl's

Reuters
·
Nov 25, 2025

Esperion Therapeutics Initiated at Overweight by Piper Sandler

Dow Jones
·
Nov 25, 2025

Piper Sandler Initiates Coverage on Esperion Therapeutics With Overweight Rating

MT Newswires Live
·
Nov 25, 2025

BUZZ-Esperion gains after Piper Sandler initiates with 'overweight' rating

Reuters
·
Nov 25, 2025

Esperion initiated with an Overweight at Piper Sandler

TIPRANKS
·
Nov 25, 2025

U.S. RESEARCH ROUNDUP-Air Products, Hanover Insurance, Kinsale Capital

Reuters
·
Nov 25, 2025

Esperion Therapeutics Inc : Piper Sandler Initiates Coverage With Overweight Rating; Price Target $9

THOMSON REUTERS
·
Nov 25, 2025

BUZZ-U.S. STOCKS ON THE MOVE-IES Holding, Eli Lilly, Alphabet

Reuters
·
Nov 22, 2025

BRIEF-Esperion Partner Otsuka Launches Nexletol In Japan

Reuters
·
Nov 21, 2025

Esperion Receives $90 Million Payment as Otsuka Launches NEXLETOL in Japan

Reuters
·
Nov 21, 2025

Esperion Partner Otsuka Launches Nexletol® in Japan for the Treatment of Hypercholesterolemia

THOMSON REUTERS
·
Nov 21, 2025

Esperion Therapeutics: Under Agreement, Esperion Will Receive $90 Mln in a Near Term Payment as a Result of the Recent Otsuka Achievements

THOMSON REUTERS
·
Nov 21, 2025

Esperion Therapeutics: Also Eligible to Receive Additional Sales Milestone Payments Based on Total Net Sales Achievements by Otsuka in Japan

THOMSON REUTERS
·
Nov 21, 2025

Esperion Therapeutics Says Health Canada Grants Marketing Approval for Nilemdo

MT Newswires Live
·
Nov 18, 2025

Health Canada Approves Esperion’s NILEMDO for LDL-Cholesterol Reduction in At-Risk Canadians

Reuters
·
Nov 18, 2025

Esperion Therapeutics Inc -Commercial Launch for Nilemdo Is Expected in Q2 2026

THOMSON REUTERS
·
Nov 18, 2025

HLS Therapeutics Inc - Commercial Launch Expected in Q2 2026

THOMSON REUTERS
·
Nov 18, 2025